 Shanta Zimmer
Concepts (292)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 12 | 2021 | 448 | 1.460 |
Why?
| | Influenza A Virus, H1N1 Subtype | 8 | 2011 | 136 | 1.300 |
Why?
| | Physician-Patient Relations | 4 | 2016 | 521 | 0.950 |
Why?
| | Physicians, Women | 1 | 2020 | 47 | 0.880 |
Why?
| | Vulnerable Populations | 1 | 2020 | 126 | 0.810 |
Why?
| | Communicable Diseases | 1 | 2020 | 107 | 0.810 |
Why?
| | Neisseria meningitidis | 3 | 2007 | 17 | 0.790 |
Why?
| | Internship and Residency | 6 | 2019 | 857 | 0.780 |
Why?
| | Lymphocyte Antigen 96 | 3 | 2008 | 30 | 0.780 |
Why?
| | Coronavirus Infections | 2 | 2020 | 357 | 0.710 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 374 | 0.700 |
Why?
| | Professional Misconduct | 1 | 2016 | 12 | 0.670 |
Why?
| | Meningitis, Meningococcal | 2 | 2006 | 5 | 0.650 |
Why?
| | Faculty | 1 | 2016 | 101 | 0.640 |
Why?
| | Meningococcal Vaccines | 2 | 2006 | 43 | 0.620 |
Why?
| | Internal Medicine | 4 | 2018 | 192 | 0.590 |
Why?
| | Pennsylvania | 7 | 2021 | 103 | 0.590 |
Why?
| | Curriculum | 3 | 2019 | 744 | 0.580 |
Why?
| | Physicians | 3 | 2016 | 578 | 0.550 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 118 | 0.500 |
Why?
| | Influenza Vaccines | 6 | 2011 | 413 | 0.500 |
Why?
| | Education, Medical, Graduate | 4 | 2019 | 338 | 0.450 |
Why?
| | Education, Medical, Undergraduate | 1 | 2012 | 135 | 0.450 |
Why?
| | Reassortant Viruses | 1 | 2009 | 8 | 0.430 |
Why?
| | Computer Simulation | 9 | 2012 | 902 | 0.430 |
Why?
| | Students, Medical | 1 | 2012 | 204 | 0.420 |
Why?
| | Zoonoses | 1 | 2009 | 24 | 0.420 |
Why?
| | Orthomyxoviridae Infections | 1 | 2009 | 49 | 0.410 |
Why?
| | Communicable Diseases, Emerging | 1 | 2009 | 36 | 0.410 |
Why?
| | Lipid A | 3 | 2007 | 29 | 0.400 |
Why?
| | Toll-Like Receptor 4 | 4 | 2008 | 363 | 0.390 |
Why?
| | Paclitaxel | 1 | 2008 | 178 | 0.370 |
Why?
| | Zygomycosis | 1 | 2007 | 6 | 0.370 |
Why?
| | Cyclosporiasis | 1 | 2007 | 2 | 0.370 |
Why?
| | Dermatomycoses | 1 | 2007 | 10 | 0.360 |
Why?
| | Oxazolidinones | 2 | 2004 | 16 | 0.350 |
Why?
| | Acetamides | 2 | 2004 | 30 | 0.350 |
Why?
| | Leadership | 2 | 2020 | 259 | 0.350 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2008 | 194 | 0.350 |
Why?
| | Thiazoles | 1 | 2007 | 126 | 0.340 |
Why?
| | Betacoronavirus | 2 | 2020 | 273 | 0.340 |
Why?
| | Humans | 47 | 2021 | 104249 | 0.330 |
Why?
| | Drug Hypersensitivity | 1 | 2007 | 79 | 0.330 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2005 | 75 | 0.330 |
Why?
| | Fungi | 1 | 2007 | 111 | 0.330 |
Why?
| | Triazoles | 1 | 2007 | 135 | 0.330 |
Why?
| | Disease Outbreaks | 5 | 2010 | 285 | 0.310 |
Why?
| | History, 21st Century | 2 | 2020 | 220 | 0.310 |
Why?
| | History, 20th Century | 2 | 2020 | 350 | 0.290 |
Why?
| | Endocarditis, Bacterial | 1 | 2003 | 31 | 0.280 |
Why?
| | Enterococcus faecalis | 1 | 2003 | 28 | 0.280 |
Why?
| | Sulfonamides | 1 | 2007 | 382 | 0.270 |
Why?
| | Schools | 3 | 2021 | 314 | 0.270 |
Why?
| | Models, Molecular | 1 | 2008 | 1583 | 0.260 |
Why?
| | Models, Economic | 3 | 2012 | 56 | 0.250 |
Why?
| | Emergency Responders | 1 | 2021 | 26 | 0.230 |
Why?
| | Awards and Prizes | 1 | 2020 | 51 | 0.220 |
Why?
| | Program Evaluation | 3 | 2019 | 819 | 0.220 |
Why?
| | Crowding | 1 | 2020 | 40 | 0.220 |
Why?
| | Prisons | 1 | 2020 | 52 | 0.210 |
Why?
| | Shoulder | 1 | 2020 | 54 | 0.210 |
Why?
| | Frail Elderly | 1 | 2020 | 94 | 0.210 |
Why?
| | Anesthesiology | 2 | 2018 | 102 | 0.210 |
Why?
| | Adult | 19 | 2021 | 30359 | 0.210 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2020 | 181 | 0.210 |
Why?
| | Minority Groups | 1 | 2020 | 164 | 0.200 |
Why?
| | Nursing Homes | 1 | 2020 | 139 | 0.200 |
Why?
| | Surgery Department, Hospital | 1 | 2018 | 24 | 0.200 |
Why?
| | Financing, Organized | 1 | 2018 | 32 | 0.200 |
Why?
| | Faculty, Medical | 2 | 2018 | 209 | 0.190 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 258 | 0.190 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 101 | 0.190 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2011 | 1979 | 0.190 |
Why?
| | Point-of-Care Systems | 2 | 2017 | 139 | 0.190 |
Why?
| | Sexual and Gender Minorities | 1 | 2019 | 76 | 0.190 |
Why?
| | Urban Population | 1 | 2020 | 408 | 0.180 |
Why?
| | Preceptorship | 1 | 2017 | 58 | 0.180 |
Why?
| | Pandemics | 2 | 2020 | 585 | 0.180 |
Why?
| | Occupational Exposure | 1 | 2020 | 310 | 0.170 |
Why?
| | Rural Population | 1 | 2020 | 421 | 0.170 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 189 | 0.170 |
Why?
| | Population Surveillance | 2 | 2011 | 409 | 0.170 |
Why?
| | Female | 19 | 2021 | 59707 | 0.170 |
Why?
| | United States | 7 | 2020 | 11035 | 0.160 |
Why?
| | Societies, Medical | 1 | 2020 | 739 | 0.160 |
Why?
| | Aged | 11 | 2020 | 18934 | 0.160 |
Why?
| | Preanesthetic Medication | 1 | 2014 | 11 | 0.160 |
Why?
| | Endotoxins | 2 | 2007 | 255 | 0.150 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 273 | 0.150 |
Why?
| | Sexual Behavior | 1 | 2019 | 407 | 0.150 |
Why?
| | Cardiology | 1 | 2017 | 282 | 0.150 |
Why?
| | Antiviral Agents | 2 | 2011 | 601 | 0.150 |
Why?
| | Myocardium | 1 | 2020 | 1080 | 0.150 |
Why?
| | Male | 18 | 2021 | 58392 | 0.150 |
Why?
| | Anti-Bacterial Agents | 1 | 2003 | 1243 | 0.140 |
Why?
| | Clinical Competence | 2 | 2018 | 870 | 0.140 |
Why?
| | Binding Sites | 2 | 2008 | 1327 | 0.140 |
Why?
| | Hand Hygiene | 1 | 2013 | 7 | 0.140 |
Why?
| | Work Schedule Tolerance | 1 | 2013 | 44 | 0.140 |
Why?
| | Recombinant Proteins | 2 | 2008 | 1452 | 0.140 |
Why?
| | Macrophage Activation | 2 | 2005 | 149 | 0.140 |
Why?
| | Macrophages | 4 | 2008 | 1157 | 0.140 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2013 | 106 | 0.130 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 714 | 0.130 |
Why?
| | Patients | 1 | 2013 | 120 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 3 | 2011 | 2291 | 0.130 |
Why?
| | Antibodies, Viral | 2 | 2021 | 465 | 0.130 |
Why?
| | Social Support | 1 | 2016 | 511 | 0.130 |
Why?
| | Patient Admission | 1 | 2013 | 188 | 0.130 |
Why?
| | Hospitalization | 1 | 2020 | 1486 | 0.130 |
Why?
| | Receptors, Cell Surface | 2 | 2005 | 390 | 0.120 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 500 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2018 | 4151 | 0.120 |
Why?
| | Quality Improvement | 1 | 2019 | 803 | 0.120 |
Why?
| | Poverty Areas | 1 | 2011 | 35 | 0.120 |
Why?
| | Cyclopentanes | 1 | 2011 | 11 | 0.120 |
Why?
| | Patient Preference | 1 | 2013 | 149 | 0.120 |
Why?
| | Young Adult | 8 | 2020 | 10261 | 0.120 |
Why?
| | Students | 1 | 2016 | 424 | 0.120 |
Why?
| | Nod2 Signaling Adaptor Protein | 1 | 2011 | 30 | 0.120 |
Why?
| | Guanidines | 1 | 2011 | 48 | 0.120 |
Why?
| | Hemagglutinins | 1 | 2010 | 11 | 0.120 |
Why?
| | Communication | 1 | 2016 | 625 | 0.110 |
Why?
| | Risk Assessment | 1 | 2020 | 2934 | 0.110 |
Why?
| | Pneumococcal Infections | 1 | 2011 | 87 | 0.110 |
Why?
| | Clostridium Infections | 1 | 2011 | 60 | 0.110 |
Why?
| | Clostridium difficile | 1 | 2011 | 75 | 0.110 |
Why?
| | Quarantine | 1 | 2010 | 15 | 0.110 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 167 | 0.110 |
Why?
| | Health Care Costs | 2 | 2011 | 392 | 0.110 |
Why?
| | Health Care Rationing | 1 | 2010 | 48 | 0.110 |
Why?
| | Sarcoidosis | 1 | 2011 | 92 | 0.110 |
Why?
| | Staphylococcal Infections | 2 | 2012 | 317 | 0.110 |
Why?
| | Biomarkers | 1 | 2020 | 3163 | 0.110 |
Why?
| | Influenza A Virus, H2N2 Subtype | 1 | 2009 | 1 | 0.110 |
Why?
| | Antigenic Variation | 1 | 2009 | 10 | 0.110 |
Why?
| | Occupational Health Services | 1 | 2009 | 41 | 0.110 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 244 | 0.100 |
Why?
| | Antibody Specificity | 1 | 2009 | 185 | 0.100 |
Why?
| | Middle Aged | 12 | 2021 | 27633 | 0.100 |
Why?
| | Haplotypes | 1 | 2011 | 535 | 0.100 |
Why?
| | Birds | 1 | 2009 | 87 | 0.100 |
Why?
| | Cross Infection | 1 | 2011 | 220 | 0.100 |
Why?
| | Genome, Viral | 1 | 2009 | 134 | 0.100 |
Why?
| | Asthma | 1 | 2020 | 1861 | 0.100 |
Why?
| | Meningitis, Bacterial | 1 | 2008 | 46 | 0.090 |
Why?
| | Pichia | 1 | 2007 | 16 | 0.090 |
Why?
| | Disease Management | 1 | 2012 | 559 | 0.090 |
Why?
| | Carbohydrate Conformation | 1 | 2007 | 31 | 0.090 |
Why?
| | Primary Prevention | 1 | 2010 | 218 | 0.090 |
Why?
| | Cyclospora | 1 | 2007 | 2 | 0.090 |
Why?
| | Antiparasitic Agents | 1 | 2007 | 4 | 0.090 |
Why?
| | Renal Dialysis | 1 | 2011 | 316 | 0.090 |
Why?
| | Tubulin | 1 | 2008 | 136 | 0.090 |
Why?
| | Linezolid | 2 | 2004 | 17 | 0.090 |
Why?
| | Protein Structure, Secondary | 1 | 2008 | 402 | 0.090 |
Why?
| | Swine | 1 | 2009 | 674 | 0.090 |
Why?
| | District of Columbia | 3 | 2011 | 19 | 0.090 |
Why?
| | Surface Properties | 1 | 2008 | 408 | 0.090 |
Why?
| | Species Specificity | 1 | 2008 | 653 | 0.090 |
Why?
| | Phylogeny | 1 | 2010 | 757 | 0.080 |
Why?
| | Neonatal Screening | 1 | 2008 | 180 | 0.080 |
Why?
| | Cell Line | 3 | 2008 | 2946 | 0.080 |
Why?
| | Antifungal Agents | 1 | 2007 | 144 | 0.080 |
Why?
| | Aged, 80 and over | 5 | 2020 | 6518 | 0.080 |
Why?
| | Vancomycin Resistance | 1 | 2005 | 14 | 0.080 |
Why?
| | Chronic Disease | 1 | 2012 | 1686 | 0.080 |
Why?
| | Enterococcus | 1 | 2005 | 17 | 0.080 |
Why?
| | HIV Infections | 1 | 2019 | 2101 | 0.080 |
Why?
| | Risk Factors | 4 | 2021 | 8467 | 0.080 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 84 | 0.080 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 918 | 0.080 |
Why?
| | Evolution, Molecular | 1 | 2009 | 446 | 0.080 |
Why?
| | Child, Preschool | 6 | 2021 | 9106 | 0.080 |
Why?
| | Efficiency | 2 | 2019 | 93 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2011 | 723 | 0.070 |
Why?
| | Transfection | 1 | 2007 | 1002 | 0.070 |
Why?
| | Vaccines, Conjugate | 1 | 2004 | 46 | 0.070 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2004 | 91 | 0.070 |
Why?
| | Receptors, Immunologic | 1 | 2005 | 225 | 0.070 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2004 | 85 | 0.070 |
Why?
| | Animals | 5 | 2009 | 34264 | 0.070 |
Why?
| | Lipopolysaccharides | 2 | 2005 | 928 | 0.070 |
Why?
| | Bacteremia | 1 | 2005 | 170 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2242 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 1194 | 0.070 |
Why?
| | Infant | 4 | 2012 | 7629 | 0.060 |
Why?
| | Odds Ratio | 2 | 2021 | 1033 | 0.060 |
Why?
| | Protein Binding | 1 | 2008 | 2098 | 0.060 |
Why?
| | Models, Statistical | 3 | 2011 | 685 | 0.060 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 214 | 0.060 |
Why?
| | Adolescent | 6 | 2021 | 17541 | 0.060 |
Why?
| | Referral and Consultation | 2 | 2017 | 548 | 0.060 |
Why?
| | Influenza B virus | 1 | 2021 | 33 | 0.060 |
Why?
| | Cohort Studies | 3 | 2021 | 4560 | 0.060 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 3197 | 0.060 |
Why?
| | Child | 6 | 2021 | 15648 | 0.060 |
Why?
| | Absenteeism | 1 | 2021 | 42 | 0.060 |
Why?
| | Germany | 1 | 2020 | 74 | 0.060 |
Why?
| | Monte Carlo Method | 2 | 2011 | 167 | 0.060 |
Why?
| | Membrane Cofactor Protein | 2 | 2011 | 15 | 0.060 |
Why?
| | Sex Factors | 2 | 2018 | 1913 | 0.060 |
Why?
| | Mutation | 1 | 2011 | 3174 | 0.060 |
Why?
| | Age Factors | 2 | 2021 | 3221 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2007 | 852 | 0.050 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 200 | 0.050 |
Why?
| | Schools, Medical | 1 | 2019 | 99 | 0.050 |
Why?
| | Cost-Benefit Analysis | 2 | 2011 | 515 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2007 | 4339 | 0.050 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2019 | 113 | 0.050 |
Why?
| | Feedback | 1 | 2018 | 129 | 0.050 |
Why?
| | Regression Analysis | 1 | 2021 | 1158 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1126 | 0.040 |
Why?
| | Models, Educational | 1 | 2017 | 90 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2018 | 158 | 0.040 |
Why?
| | Focus Groups | 1 | 2018 | 331 | 0.040 |
Why?
| | Respiration, Artificial | 1 | 2020 | 513 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2021 | 774 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2020 | 531 | 0.040 |
Why?
| | Mice | 3 | 2008 | 14765 | 0.040 |
Why?
| | Infant, Newborn | 3 | 2012 | 4741 | 0.040 |
Why?
| | Survival Rate | 1 | 2020 | 1755 | 0.040 |
Why?
| | European Continental Ancestry Group | 2 | 2011 | 1337 | 0.040 |
Why?
| | Educational Measurement | 1 | 2018 | 300 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 230 | 0.040 |
Why?
| | Logistic Models | 1 | 2020 | 1984 | 0.040 |
Why?
| | Toll-Like Receptors | 2 | 2005 | 189 | 0.040 |
Why?
| | Biomedical Research | 1 | 2019 | 574 | 0.030 |
Why?
| | Body Mass Index | 1 | 2020 | 2001 | 0.030 |
Why?
| | Prognosis | 1 | 2020 | 3289 | 0.030 |
Why?
| | Preoperative Care | 1 | 2014 | 358 | 0.030 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2011 | 25 | 0.030 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2011 | 39 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2012 | 122 | 0.030 |
Why?
| | Decision Trees | 1 | 2011 | 80 | 0.030 |
Why?
| | Patient Participation | 1 | 2014 | 343 | 0.030 |
Why?
| | Patient Safety | 1 | 2014 | 311 | 0.030 |
Why?
| | Stochastic Processes | 1 | 2011 | 72 | 0.030 |
Why?
| | Signal Transduction | 1 | 2005 | 4845 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2011 | 117 | 0.030 |
Why?
| | Colorado | 1 | 2021 | 4483 | 0.030 |
Why?
| | Data Collection | 1 | 2013 | 674 | 0.030 |
Why?
| | Streptococcus pneumoniae | 1 | 2011 | 122 | 0.030 |
Why?
| | Diarrhea | 1 | 2011 | 171 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2011 | 328 | 0.030 |
Why?
| | Calibration | 1 | 2010 | 137 | 0.030 |
Why?
| | Gene Frequency | 1 | 2011 | 552 | 0.030 |
Why?
| | Mass Vaccination | 1 | 2009 | 19 | 0.030 |
Why?
| | Cost of Illness | 1 | 2012 | 270 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 440 | 0.030 |
Why?
| | Attitude to Health | 1 | 2013 | 390 | 0.030 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 133 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 2842 | 0.030 |
Why?
| | Travel | 1 | 2010 | 132 | 0.030 |
Why?
| | Immunization Programs | 1 | 2011 | 189 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2014 | 753 | 0.030 |
Why?
| | Anxiety | 1 | 2014 | 664 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1148 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2011 | 308 | 0.020 |
Why?
| | Workplace | 1 | 2009 | 200 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 265 | 0.020 |
Why?
| | Occupational Health | 1 | 2009 | 178 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2011 | 384 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2011 | 1152 | 0.020 |
Why?
| | Pilot Projects | 1 | 2011 | 1323 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 420 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2008 | 677 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2010 | 404 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 2038 | 0.020 |
Why?
| | African Americans | 1 | 2011 | 1040 | 0.020 |
Why?
| | Gram-Negative Bacteria | 1 | 2005 | 63 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2005 | 251 | 0.020 |
Why?
| | Incidence | 1 | 2011 | 2317 | 0.020 |
Why?
| | Growth | 1 | 2004 | 63 | 0.020 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2005 | 113 | 0.020 |
Why?
| | Sugar Acids | 1 | 2004 | 2 | 0.020 |
Why?
| | U937 Cells | 1 | 2004 | 29 | 0.020 |
Why?
| | Respiratory Burst | 1 | 2004 | 39 | 0.020 |
Why?
| | DNA | 1 | 2011 | 1384 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 3662 | 0.020 |
Why?
| | Vaccination | 1 | 2011 | 850 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2017 | 8608 | 0.020 |
Why?
| | Antigens, Surface | 1 | 2004 | 151 | 0.020 |
Why?
| | Toll-Like Receptor 2 | 1 | 2004 | 152 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 555 | 0.020 |
Why?
| | Models, Biological | 1 | 2010 | 1842 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 355 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2008 | 3225 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2005 | 870 | 0.010 |
Why?
| | Time Factors | 1 | 2009 | 7066 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 1868 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2008 | 10064 | 0.010 |
Why?
|
|
Zimmer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|